Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (29963)	1/8/2000 1:29:00 PM
From: WTDEC	Read Replies (1) \| Respond to of 32384

Henry, thanks for posting the stories. Stockholders should feel good about LGND's work as well as benefiting from the eventual catch-up of the stock price with its intrinsic value. Walter

To: Henry Niman who wrote (29963)	1/8/2000 2:38:00 PM
From: psh	Read Replies (3) \| Respond to of 32384

Henry, It appears that the main side effects are increase in triglycerides and hypothyroidism, is that correct? Do you know if these are dose related and what the volume of distribution for the drug is? I'm thinking about potential use as breast ca prophylaxis or other early stage diseases. If these are the main side effects then it can potentially be used for a wide range of malignancies (assuming efficacy). We use more toxic drugs in cardiology for much more benign diseases. Good luck.

To: Henry Niman who wrote (29963)	1/8/2000 3:00:00 PM
From: Torben Noerup Nielsen	Read Replies (1) \| Respond to of 32384

Henry, If the drug has even a reasonable chance of retarding tumor growth, patients will find a doctor who will write the prescription. Moreover, news will spread fast through the breast cancer support groups. There's also plaque psoriasis to consider. If Targretin happens to be effective there, it's a substantial market since that is a life-long disease. But we need the trial results. One more positive Targretin trial should be sufficient to cause LGND to become fairly valued in very short order. Incidentally, I wonder how many doctors might try Targretin on non-refractory CTCL. Reading the case histories Henry posted, current treatments sound like cruel and unusual punishment and with the low and manageable toxicity of Targretin, I don't see why it wouldn't be used as a first line treatment in short order. Use small dosages to start with to establish individual tolerances and see how effective it is against the disease. Then ramp up the dosage till you either get results against the disease or run into tolerance problems. Thanks, Torben